Initial 200-Unit Sale previously announced on April 24, 2025, Targeted Specialized Knee Surgeons in U.S. Healthcare Network

Toronto, Ontario--(Newsfile Corp. - September 24, 2025) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) ("Therma Bright" or the "Company"), a developer and investment partner specializing in advanced diagnostic and medical device technologies, is pleased to announce a strategic partnership with Gen-X Med, a specialized medical product distributor based in Arlington, Texas. The partnership was hatched after the initial sale of 200 Venowave™ VW5 units that targeted patients that had undergone specialized knee surgeries by trained surgeons with expertise in the procedure. Specialized knee surgeries represent a high value and growing segment of the U.S. healthcare market.

"We are pleased to partner with Therma Bright in offering the Venowave™ VW5 to our doctor network," shared Beau Wood, President, Gen-X Med. "We've seen great patient success with the initial 200-unit purchase and anticipate placing additional orders as we ramp up awareness and adoption of this special vascular compression therapy solution."

Rob Fia, CEO of Therma Bright, added, "This partnership with Gen-X Med is a strategic step in expanding Venowave's presence into a focused and high-value market segment. We believe the Venowave™ offers significant advantages for patients and the U.S. healthcare system by reducing post-surgical complications and costly readmissions, which aligns with our mission to provide innovative and effective medical solutions that improve patient outcomes and create value."

According to a November 2024 press announcement from Straits Research, the global compression therapy market was valued at $4.18 billion in 2024 and is projected to grow to $6.72 billion by 2033, representing a compound annual growth rate (CAGR) of 7.30% from 2025 to 2033.

About the Venowave™ VW5
The Venowave™ VW5 is a compact, battery-operated peristaltic pump designed as a portable, at-home solution for the treatment of circulatory disorders. When positioned below the knee, the FDA-designated Durable Medical Equipment (DME) device generates a gentle, wave-like motion to improve blood circulation and lymphatic function. Clinically shown to enhance venous blood flow by 64% after just two minutes of use and 88% after 50 minutes, the Venowave™ is the only Medicare-approved reimbursable mobile mechanical compression system available in the U.S. under its HCPCS code E0683. It provides a comfortable and simple treatment solution to accelerate post-operative recovery while managing pain and swelling.

About Gen-X Med
Gen-X Med is an Arlington, Texas-based distributor committed to providing healthcare professionals with specialized, vetted products and exceptional client care. The company's portfolio includes durable medical equipment (DME) products, with a focus on sourcing and providing the most qualified products and services to meet the needs of its clients.
Visit: http://www.genxmed.net/

About Therma Bright Inc.
Therma Bright develops and partners on cutting-edge diagnostic and medical device technologies that address key healthcare challenges. Therma Bright Inc. trades on the (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX). Visit: (https://www.thermabright.com).

Follow us on X:
https://x.com/Bright_Therma

FORWARD-LOOKING STATEMENTS
Certain statements in this news release constitute "forward-looking" statements. These statements relate to future events such as future sales of Venowave and related technology as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. Forward-looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether such results will be achieved. Actual results could differ materially from those anticipated due to several factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether because of new information, future events or otherwise, except as required under applicable securities regulations.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/267679